MASTERINVEST Kapitalanlage GmbH Increases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

MASTERINVEST Kapitalanlage GmbH grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 86.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,996 shares of the medical research company’s stock after purchasing an additional 3,246 shares during the period. MASTERINVEST Kapitalanlage GmbH’s holdings in Thermo Fisher Scientific were worth $3,439,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Assetmark Inc. raised its position in Thermo Fisher Scientific by 22.9% in the 4th quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock valued at $21,819,000 after purchasing an additional 7,023 shares in the last quarter. North Dakota State Investment Board purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $7,505,000. Confluence Investment Management LLC raised its holdings in Thermo Fisher Scientific by 14.2% in the fourth quarter. Confluence Investment Management LLC now owns 95,064 shares of the medical research company’s stock valued at $55,085,000 after acquiring an additional 11,841 shares in the last quarter. Argent Capital Management LLC lifted its stake in Thermo Fisher Scientific by 45.8% in the fourth quarter. Argent Capital Management LLC now owns 52,359 shares of the medical research company’s stock worth $30,340,000 after acquiring an additional 16,439 shares during the last quarter. Finally, Union Bancaire Privee UBP SA increased its position in shares of Thermo Fisher Scientific by 266.3% in the 4th quarter. Union Bancaire Privee UBP SA now owns 53,091 shares of the medical research company’s stock valued at $30,764,000 after purchasing an additional 38,597 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 1.2%

TMO stock opened at $534.99 on Wednesday. The company has a market cap of $198.81 billion, a price-to-earnings ratio of 29.41, a price-to-earnings-growth ratio of 2.34 and a beta of 0.87. The company has a fifty day moving average price of $480.57 and a 200 day moving average price of $515.34. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. Thermo Fisher Scientific Inc. has a 12 month low of $403.36 and a 12 month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. During the same period in the previous year, the business posted $5.15 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.34%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on TMO. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Wolfe Research started coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price target on the stock. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research report on Monday, July 6th. Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. Finally, KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $602.14.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.